Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Weight loss drugs are set to remain well in focus of investors this year, as the rollout of such treatment looks to even affect the food industry, Liberum analysts say. Following Novo Nordisk (NYSE...

Stifel has identified Novo Nordisk (NYSE:NVO), Merck KGaA, and Sandoz as top picks in the European pharmaceutical sector for the first quarter of 2024, according to its recent research note. Novo N...

Eli Lilly manufactures medication similar to Ozempic called Mounjaro. Zepbound, which has the same active ingredient as Mounjaro, was recently approved for treating obesity.

Ozempic was a big factor behind Novo Nordisk's success last year, but not the biggest growth driver. The drugmaker had a lot of good news that boosted its stock price in 2023.

Novo Nordisk said on Friday it resumed shipments of weight loss drug Wegovy in the 1.7 milligram dose in early January, following a short-term stock-out in the U.S. in mid-December last year.

Novo Nordisk is the market leader of the fast-growing obesity care industry, which is expected to grow above 20% CAGR until 2030. The company raised three times its guidance during 2023, driven by ...

In the most recent trading session, Novo Nordisk (NVO) closed at $106.95, indicating a +0.52% shift from the previous trading day.

Novo Nordisk A/S (NVO) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript

Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.

Denmark's Novo Nordisk said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling blood sugar level in people with type 2 diabetes com...

Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.

The pharmaceutical company has two new research partners. It signed separate but similar deals with Omega Therapeutics and Cellarity.

Shares of Novo Nordisk (NVO), the market leader in weight-loss drugs, jumped more than 4% Thursday after the company said it inked research agreements with two American biotech firms.